CAU Scholar's Space: Kang, Won Ku

Detailed Information

Kang, Won Ku (강원구)

약학대학 (약학부)

Research Area: 약동학/약력학 모델링 및 시뮬레이션, 신약개발을 위한 의약품 합성 및 분석기술, 메타리셉톰 및 후성유전체 기반 난치성질환 치료제 연구, Pharmacokinetics, Analytical Methods in Pharmacology, Physiologically Based Pharmacokinetic Modeling

Tel 02-820-5601
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Pharmacokinetics:21||pharmacokinetics:21||LC/MS/MS:18||LCMS/MS:12||Rat:11||HPLCMS/MS:9||MS:7||Rat plasma:7||Metabolism:6||Sibutramine:5||Bioequivalence:5||bioequivalence:5||pharmacokinetic:4||benidipine:4||Rats:4||Caffeine:4||idarubicin:4||HPLC:4||verapamil:4||pharmacodynamics:4||Bioavailability:3||Cytotoxicity:3||column liquid chromatography:3||Apoptosis:3||In vivo:3||Toxicity:3||Metaanalysis:3||heart:3||Pglycoprotein:3||7OSuccinyl macrolactin A:3||Aceclofenac:3||Drug interaction:3||Intravenous:3||Cytochrome P450:3||rabbits:3||Pharmacokinetic modeling:3||Baicalin:3||LC:3||Herbdrug interaction:3||Ilimaquinone:3||cytochrome P450:2||Talniflumate:2||Telmisartan:2||Amisulpride:2||dexamethasone:2||Immunotoxicity:2||menatetrenone:2||Chiral separation:2||Intestinal microflora:2||training project:2||Doxifluridine:2||Mice:2||Baicalein:2||drugdrug interaction:2||Wnt/βcatenin pathway:2||Xanthorrhizol:2||aceclofenac:2||Kinetics:2||Rabbit:2||Randomized controlled trials:2||CYP2J2:2||omeprazole:2||Regulatory science:2||NONMEM:2||panduratin A:2||Rutaecarpine:2||Fermentation:2||ELFEMF:2||SGSP1:2||guidance:2||periodontitis:2||pharmacodynamic:2||pharmacokineticpharmacodynamic modelling:2||Niflumic acid:2||Hepatotoxicity:2||platelet aggregation:2||biomarker:2||Atopic dermatitis:2||caffeine:2||population pharmacokinetics:2||Food:2||Capillary electrophoresis:2||cefetamet:2||Gabapentin:2||rat:2||rats:2||Human plasma:2||Stability:2||Sulfisoxazole:2||Cefixime:2||saturable uptake:2||Panduratin A:2||Systemic exposure:2||Macrolactin A:2||ERE:1||ERK1/2:1||ERα:1||Ebastine:1||Education:1||Enalapril:1||Enantiomer migration order:1||Enantioselective pharmacokinetics:1||Enantioseparation:1||Epiilimaquinone:1||Etanercept:1||Ethanol:1||Extrapolation:1||FPP3:1||Fatty acid synthase:1||Fc epsilon RI:1||Fecalase:1||Fenofibrate:1||FirstInMan dose:1||Fluoxetine:1||Food effect:1||Fooddrug interactions:1||GCMS:1||Galgeuntang:1||Gallic acid:1||Gastrointestinal system:1||Gender:1||General medical journals:1||Genipin:1||Geniposide:1||Glimepiride:1||Glutathione:1||GlyPro:1||GlyProHyp:1||Glycyrrhizin:1||Gut microbiota:1||HPLCMS:1||HYP10:1||Heme oxygenase1:1||Herbal medicine:1||High concentration protein:1||High density lipoprotein:1||Highperformance liquid chromatography:1||Highly variable drug:1||Human:1||ICG001:1||IDA:1||IL2:1||IL9:1||IMI:1||Intestinal bacteria:1||Intragastric:1||Isomer:1||Japanese eel:1||Java turmeric extract:1||KRG:1||Kahweol:1||Ketoprofen:1||Kinetin riboside:1||Korean Red Ginseng:1||Korean healthy volunteers:1||LArginine:1||LCMSMS:1||Labelfree protein quantitation:1||Leptin:1||Levia®:1||Levodopa:1||Lipid peroxidation:1||M1:1||M2:1||MAPK pathway:1||MEIA:1||MFDS:1||MKK4:1||MMPs:1||Magnesium hydroxide:1||Mammalian cell cultures:1||Mast cell:1||Mast cells:1||Mesupron:1||Metabolic activation:1||Metabolic syndrome:1||Metabolites:1||Metastasis:1||Methylbetacyclodextrin:1||Mitogenactivated protein kinase:1||Monodesmethylsibutramine:1||Monodesmethylsibutramine:1||Mouse:1||NDesmethyl olanzapine:1||N1acetyl sulfisoxazole:1||N4acetyl sulfisoxazole:1||NFκB:1||NFκB pathway:1||Na+K+ATPase:1||Na+/Ca2+ exchanger:1||Naltrexone:1||Nasal delivery:1||Neovascular agerelated macular degeneration:1||Novel Ttype calcium channel blocker:1||Nrf2:1||Nuclear factorkappa B:1||OATP:1||Obesity:1||Olanzapine:1||Oleanolic acid:1||Orthotopolin riboside:1||PK/PD modeling:1||PSC 833:1||PT:1||PXR:1||Parity:1||Passive cutaneous anaphylaxis:1||Pharmacodynamics:1||Pharmacokinetic parameters:1||Pharmacokinetic(PK)/Pharmacodynamic(PD) modeling:1||Pharmacokineticpharmacodynamic modeling:1||Pharmacometrics:1||Plasma:1||Population bioequivalence:1||Population pharmacokinetics:1||ProHyp:1||Propolis:1||Prostaglandin D2:1||Protection:1||Protein microbead:1||Protein precipitation:1||Proteomics:1||Prunus persica L:1||Publication:1||Publication bias:1||QT prolongation:1||Quality of reports:1||Rat heart:1||Reporting:1||Roadmap:1||SB31:1||SCORAD:1||SGHQ2:1||STAT3:1||Salvia miltiorrhiza Bunge:1||Saturable pharmacokinetics:1||Scaled average bioequivalence:1||Serum:1||Shikimic acid:1||SimCYP:1||Simulation:1||Simvastatin:1||Skin:1||Solanum melongena:1||Solubility:1||Ssanghwatang:1||Stereoselective pharmacokinetics:1||Suprax^R:1||Symmetric dimethylarginine:1||Systematic review:1||T helper 9 cell:1||TBBPA:1||TSAHC:1||Tacrolimus:1||Tetrabromobisphenol A:1||Theophylline:1||Thioacetamide:1||Three Nacetylated metabolites:1||Topical ocular:1||Transcriptomics:1||Traxone:1||Trial registration:1||UV detection:1||Uridine:1||Urine:1||VEGF:1||VKORC1:1||Validation:1||WinNonlin:1||Wnt/betacatenin signaling:1||Zocor®:1||adverse reactions:1||afloqualone:1||allergic inflammation:1||allometric scaling:1||alveolar bone:1||anaphylaxis:1||antiinflammatory:1||antiinflammatory effect:1||antiperiodontitis:1||antioxidant:1||apoptosis:1||atopic dermatitis:1||baicalein:1||baicalin:1||betaCyclodextrin:1||bilobetin:1||bioequivalence:1||bioanalytics:1||bioavailability:1||bioinspired microneedle:1||biological evaluation of dosage forms:1||biologics:1||caffeic acid phenethyl ester:1||canalicular insert:1||cardiac glycosides:1||cardiotoxicity:1||carebastine:1||cefetamet pivoxil:1||chiral stationary phase:1||clopidogrel:1||clopidogrel besylate:1||clopidogrel metabolite (SR26334):1||colorectal cancer:1||combination drug:1||controlled and sustainedrelease systems:1||costeffectiveness analysis:1||cotinine:1||critical path:1||crossreactivity:1||cyclooxygenase:1||cyclosporine:1||cytokine:1||cytotoxicity:1||daumone:1||dehydration:1||desalkylebastine:1||diabetes mellitus:1||diclofenac:1||dietary salt:1||digoxin:1||disease progression model:1||dissolution test:1||dog:1||dog plasma:1||dosage form design and characterization:1||doxifluridine:1||doxorubicin:1||drug compendia:1||drug development:1||drug interaction:1||drug interactions:1||drug monograph:1||drugdrug interactions:1||ebastine:1||education and training:1||eggplant:1||electrospun web microneedle:1||elvasta:1||enantiomers:1||epoxide metabolite:1||ethnicity:1||fenofibrate:1||fingerroot extracts:1||fluoxetine:1||flurbiprofen:1||fluvastatin:1||gallic acid:1||gender:1||genetic variations:1||gingival tissue:1||glial cells:1||glimepiride:1||glucocorticoids:1||glutathione conjugation:1||healthy volunteers:1||hepatotoxicity:1||high exposure group:1||human daily dose:1||human liver microsomes:1||human plasma:1||human plasma samples:1||human volunteers:1||humans:1||hydrochlorothiazide:1||hydroxyebastine:1||hypertension:1||hypothermia:1||idarubicinol:1||immunotoxicity:1||in vivo:1||inflammation:1||inflammatory cytokine:1||inhibition:1||innovative medicines initiative:1||inotropism:1||inotropy:1||interindividual variability:1||intestinal microbiota:1||intravenous:1||kidney transplantation:1||korean:1||lansoprazole:1||liquid chromatography:1||lovastatin:1||macrophage:1||macrophages:1||mass spectrometry:1||mast cell:1||mast cells:1||mathematical modeling:1||matrix effect:1||menatetrenone epoxide:1||metabolic alteration:1||metabolites:1||mice:1||model:1||monolithic silica column:1||mouse plasma:1||myocardial metabolism of ebastine:1||naltrexone:1||nanoESIMS:1||nateglinide:1||national health insurance:1||new drug development process:1||nicotine:1||nifedipine:1||nitric oxide synthase:1||nonsmall cell lung cancer:1||nonlinear mixed effect modeling:1||nonlinear mixedeffects modeling:1||norfluoxetine:1||norverapamil:1||octylonium in human plasma:1||ocular implant:1||oleohydrogel:1||olmesartan medoxomil:1||orthotopolin riboside:1||osteoblastogenesis:1||osteoclastogenesis:1||osteoporosis:1||p53 pathway:1||parameters:1||parentmetabolite pharmacokinetic model:1||patch:1||patient access:1||pediatrics:1||percutaneous absorption:1||perfused rat heart:1||periodontal inflammation:1||peroxiredoxin1:1||pharmaceutics and drug delivery:1||pharmacokinetic/pharmacodynamic modelling:1||physiologically based pharmacokinetics:1||plasma:1||plasma samples:1||population analysis:1||population pharmacokinetic:1||population pharmacokinetic pharmacodynamic:1||primary metabolites:1||proinflammatory cytokines:1||proinflammatory mediators:1||propolis:1||protein degradation:1||prothrombin time:1||quinidine:1||rabbit plasma:1||rat plasma:1||regulatory science education:1||reimbursement:1||resveratrol:1||risksharing agreement:1||rivaroxaban:1||rivastigmine:1||sibutramine base:1||simvastatin:1||skin absorptin:1||skin barrier:1||slow receptorbinding model:1||solid dispersion:1||solidphase extraction:1||solubility:1||sparfloxacin:1||stalk:1||stem cell transplantation:1||stereoselectivity:1||stroke patients:1||sulfonamide allergy and hypersensitivity:1||sulfonamide medications:1||surrogate endpoint:1||sustained drug delivery:1||tandem mass spectrometry:1||terpinyl acetate:1||theophylline:1||tiletamine:1||torasemide:1||uridine:1||urine:1||vascular effects:1||vasoconstriction:1||water:1||wearable microneedle:1||zolazepam:1||1Bromobutane:1||zonisamide:1||1Furan2yl3pyridin2ylpropenone:1||1bromohexane:1||2'Hydroxy3', 4'methylenedioxy3,4,5trimethoxychalcone:1||3OAcetyloleanolic acid:1||4 'Hydroxydiclofenac:1||4 'Hydroxydiclofenac, Diclofenac:1||4'Hydroxyaceclofenac:1||4'Hydroxydiclofenac:1||4'hydroxyaceclofenac:1||4'hydroxydiclofenac:1||5Fluorouracil:1||6betanaltrexol:1||ABCB1 haplotypes:1||ADEs:1||ADRs:1||AMPK:1||API2000:1||API4000:1||APTT:1||Abietane diterpenoids:1||Absolute bioavailability:1||Active metabolite:1||Adiponectin:1||Advanced breast cancer:1||Adverse drug events:1||Adverse drug reaction:1||Adverse drug reactions:1||Afloqualone:1||Allometric scaling:1||Ankylosing spondylitis:1||Anti bodyforming cells:1||Arbutin:1||Asymmetric dimethylarginine:1||Atorvastatin:1||BPE:1||Bacterial metabolism:1||Batsch:1||Bifidobacterium:1||Binding constant:1||Bioassayguided isolation:1||Biomarker candidates:1||Boesenbergia pandurata Roxb.:1||Bone mineral density:1||Breast cancer:1||Broussochalcone A:1||Butyl paraben:1||C/EBPβ:1||CGK012:1||CONSORT for abstracts:1||CYP:1||CYP1A2:1||CYP1B1:1||CYP2J:1||CYP3A4:1||Capsaicin:1||Cardiovascular drug:1||Cell biology:1||Cepirin^R:1||Chiral selector:1||Chrysin:1||Clarithromycin:1||Clinical trial pharmacist:1||Clinical trial pharmacy:1||Clinical trials:1||Colon and liver cancers:1||Computerized surveillance system:1||Conjugated linoleic acid:1||Conjugation:1||Contrast media:1||Coulometric ECD:1||Curcuma xanthorrhiza:1||Current status:1||Cyclosporine:1||Cytokines:1||DDI:1||Daumone:1||Decursinol angelate:1||Deproteinization:1||Didesmethylsibutramine:1||Diacetyl sulfiaoxazole:1||Diallyl sulfide:1||Diclofenac:1||Didesmethylsibutramine:1||Dienetichron plot:1||Dog Plasma:1||Dog plasma:1||Dosing regimen:1||Drug Review:1||Drug absorption:1||Drug metabolism:1||Ductal carcinoma in situ:1||Duloxetine:1||Duration of therapy:1||

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE